Stakeholder News
The CREID Network collaborates with a wide variety of external stakeholders including from the US Government, foreign governments, multilateral institutions such as the World Health Organization, foundations and nonprofits, such as CEPI, Wellcome Foundation, and the private sector. If you are interested in exploring a collaboration with the CREID Network, please contact info@creid-network.org.
|
|
|
New survey from Abbott finds epidemiologists believe viral and mosquito-borne pathogens are priority concerns for disease outbreaks
The Abbott Pandemic Defense Coalition is a private sector collaborator of the CREID Network and they recently participated in the 2024 CREID Network Annual Meeting.
Abbott announced the findings of a new survey among leading infectious disease experts around the world on the state of pandemic preparedness and found that while most agree that preparation has improved since the COVID-19 pandemic, respondents say significant gaps remain in building surveillance programs to identify emerging pathogens, public health funding and having adequate testing infrastructure capabilities.
The survey, commissioned by the Abbott Pandemic Defense Coalition, asked more than 100 experts in virology, epidemiology and infectious diseases around the world about their priorities for addressing the gaps in readiness for disease outbreaks, their views on how the changing environment is impacting infectious diseases, and their suggestions for building a resilient healthcare system capable of identifying and responding to emerging disease outbreaks around the world.
CREID Network members were some of the experts who completed the survey. These findings highlight the need for ongoing support for networks like CREID as well as the need for better collaboration among networks and private industry partners to build and maintain key infrastructure that will be needed for future outbreaks.
 |
|
|
NIH/NIAID Establishes New Pandemic Preparedness
Research Network
Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP)
ReVAMPP is a pandemic preparedness research network designed to conduct fundamental basic to investigational new drug-enabling translational research on representative viruses, or “prototype pathogens,” within specific nine viral families (Flaviviruses, Paramyxoviruses, Picornaviruses, Togaviruses, Arenaviruses, Hantaviruses, Nairoviruses, Phenuiviruses, and Peribunyaviruses). Currently, many of the diseases caused by these pathogens have no available vaccines or therapeutics, and investing in this research is key to preparing for potential public health crises—both in the United States and around the world. NIH’s National Institute of Allergy and Infectious Diseases (NIAID) expects to commit approximately $100 million per year to fund the program.
ReVAMMP expands the NIAID ecosystem around Pandemic Preparedness and it is anticipated that there will be close collaboration and cross-network sharing between CREID and ReVAMPP investigators. The CREID international EID research capacity, cohort-based surveillance work, and ground-breaking work in pathogen transmission, pathogenesis, and host responses, is essential to the success of the medical countermeasure development work proposed in ReVAMPP.
|
|
|
Research Center Updates
The October 2024 quarterly newsletter features 2 of the CREID Research Centers: EpiCenter and PICREID. These 2 Research Centers work in Peru, Uganda, and the US (EpiCenter); and Cambodia, Cameroon, France, Senegal, and Turkey (PICREID).
Please see more information about each of the 9 Research Centers at the CREID Network website.
|
|
|
Jalika Joyner, a UC Davis PhD student, conducting laboratory research and cross-training in Uganda. |
|
EpiCenter
To enhance understanding of arbovirus and filovirus epidemiology, the EpiCenter has collaborated with Tetracore to develop two multiplex Luminex bead-based serology assays. Validation of these assays is ongoing, comparing results to neutralization tests and positive control sera sets. Additionally, study samples from Peru have been tested for Mayaro and Venezuelan equine encephalitis viruses using a microneutralization assay, with confirmation through endpoint titers, and risk factor analyses relating test results to demographic, occupational, and environmental factors.
-----
As the EpiCenter returns to communities to share study findings, they are also refining and distributing risk communication tools. The field team in Peru has developed a "Living Safely with Bats" educational book, tailored to how people typical encounter bats in the Peruvian Amazon, with talking points translated into Spanish. This resource will soon be available for download on the EpiCenter website.
Award Number U01AI151814
|
|
|
PICREID
PICREID investigators from the Centre Pasteur du Cameroun and the Institut Pasteur du Cambodge are in Japan for training in sero-neutralization techniques at Hokkaido University – International Joint Research Institute for Zoonotic Diseases. This training focuses on neutralization assays and production of VSV-based pseudotyped viruses enabling the investigators to validate test results obtained in the framework of PICREID research.
-----
PICREID collaborator Dr. Tineke Cantaert was a featured speaker in the LABEX IBEID Conference “Adapting to Change: Emerging Infectious Diseases in a Shifting Climate” in Paris in October. With PICREID funding, a single cell RNA sequencing pipeline was established at Institut Pasteur du Cambodge. Dr. Cantaert presented unpublished data where she showed the associations of specific T cell subsets with a protective immune response.
Award Number U01AI151768
|
|
Researchers from Institut Pasteur du Cambodge and Centre Pasteur du Cameroun participating in training on sero-neutralization at the International Joint Research Institute for Zoonotic Diseases in Japan. |
|
|
|
CREID Research Centers
 |
|
|
|
|
|
|
|
|
